4th May, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that Clive Dix has been appointed Chief Executive Officer with immediate effect.
Clive joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015. Sam Williams, Non-Executive Director, will become Interim Chairman whilst a search for a new Chairman is undertaken.
Commenting on the announcement, Clive Dix said: “Having seen from an executive position the potential of the platform to generate entirely new compounds against high-value therapeutic targets more rapidly and efficiently than any technology I’ve come across before and having witnessed the interest we’re receiving in C4X Discovery, I am delighted to take the helm on a full-time basis. I have never been more excited by a company than this one.”
Dr Dix is widely recognised as one of the leading figures in the UK biotechnology sector, combining track records as a serially successful entrepreneur and an experienced pharmaceutical R&D executive. Most recently, Dr Dix was CEO of Convergence Pharmaceuticals, which was sold to Biogen in January 2015 for $675m. Prior to that, Dr Dix enjoyed successful exits with PowderMed Limited, Auralis Limited and PowderJect Pharmaceuticals plc, where he held the roles of CEO, Chairman and Head of R&D, respectively. Before his move into biotechnology, Dr Dix was UK Research Director for GlaxoWellcome. He currently serves as Chairman of Touchlight Genetics Ltd and Centauri Therapeutics Ltd, and was Chairman of the UK BioIndustry Association (BIA) from 2008-2010.